NASDAQ:INVA - Innoviva Stock Price, Forecast & News

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

Innoviva Inc (NASDAQ:INVA) posted its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $0.36 earnings per share for the quarter, missing the consensus estimate of $0.37 by $0.01. The biotechnology company earned $65.38 million during the quarter. Innoviva had a return on equity of 168.69% and a net margin of 141.80%. View Innoviva's Earnings History.

Innoviva is scheduled to release their next quarterly earnings announcement on Wednesday, February 5th 2020. View Earnings Estimates for Innoviva.

Media coverage about INVA stock has trended negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Innoviva earned a coverage optimism score of -2.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Innoviva.

Innoviva saw a decline in short interest in November. As of November 15th, there was short interest totalling 11,200,000 shares, a decline of 6.4% from the October 31st total of 11,960,000 shares. Based on an average daily volume of 573,700 shares, the short-interest ratio is presently 19.5 days. Approximately 16.5% of the company's stock are short sold. View Innoviva's Current Options Chain.

Some companies that are related to Innoviva include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Exelixis (EXEL), Gilead Sciences (GILD), Micron Technology (MU), Advanced Micro Devices (AMD), Intercept Pharmaceuticals (ICPT), ImmunoGen (IMGN), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), ZIOPHARM Oncology (ZIOP) and Fate Therapeutics (FATE).

Innoviva's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.06%), Man Group plc (1.49%), Nomura Holdings Inc. (1.04%), Chicago Equity Partners LLC (0.46%), Millennium Management LLC (0.42%) and Assenagon Asset Management S.A. (0.37%). Company insiders that own Innoviva stock include Eric Desparbes, Geoffrey Hulme, George B Abercrombie, George Bickerstaff, Marianne Zhen and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.

INVA stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Nomura Holdings Inc., State Street Corp, Alberta Investment Management Corp, Chicago Equity Partners LLC, James Investment Research Inc., Dupont Capital Management Corp and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Innoviva.

INVA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of New Jersey Common Pension Fund D, Millennium Management LLC, Squarepoint Ops LLC, First Trust Advisors LP, Barclays PLC, SG Americas Securities LLC and Redwood Investment Management LLC. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme and George Bickerstaff. View Insider Buying and Selling for Innoviva.

Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INVA stock can currently be purchased for approximately $13.76.

Innoviva has a market capitalization of $1.39 billion and generates $261 million in revenue each year. The biotechnology company earns $395.05 million in net income (profit) each year or $3.53 on an earnings per share basis. Innoviva employs 6 workers across the globe.View Additional Information About Innoviva.

The official website for Innoviva is http://www.inva.com/.

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]